Jump to contentJump to search

Core competencies for postdoctoral fellows and young scientists

An academic career can have very diverse goals, which can be pursued individually depending on one's interests. To obtain a university professorship, both a strong interest in research and a passion for teaching are prerequisites for achieving this career goal. In addition to the professional requirements, the young scientists should also have additional key qualifications that support their everyday research work.

The Faculty attaches particular importance to the continuous training of young scientists and the qualified supervision of doctoral candidates. Applicants for admission to habilitation must provide evidence of at least four continuing education courses on core competencies for young scientists and university teachers. Participation in further training to ensure good scientific practice is mandatory.

Wir gratulieren Ulla Gerling-Driessen zur erfolgreich eingeworbenen Vernetzungsförderung

Zoom

 

This  is a collaborative project with Dr. Jonathan Lim (Institute of Neuropathology, UKD)

About the project: The major oncogenic driver in 25-30% of all human cancers arises from abnormal activation of RAS signaling pathways. Moreover, a number of mutant RAS-driven cancers such as pancreatic adenocarcinoma, and cancers with constitutive RAS signaling, such as glioblastoma, remain incurable. This drives the impetus for novel and more efficacious therapeutic strategies. The focus of the project is to gain a systems-level understanding of how oncogenic signaling from RAS activation leads to remodeling of the glycoproteome, an area that is poorly understood. We employ the use of engineered cell lines, bioorthogonal chemistry, and targeted mass spectrometry approaches to obtain a global view of glycan and proteome changes, as well as to specifically investigate how some of these changes directly contribute to tumorigenic phenotypes. These mechanisms will be recapitulated in clinically-relevant cancer models towards the development of novel therapeutic interventions for difficult-to-treat cancers.

 

Interne Vernetzungsförderung

Kategorie/n: MC Hartmann

Wir gratulieren Ulla Gerling-Driessen zur erfolgreich eingeworbenen Vernetzungsförderung

Zoom

 

This  is a collaborative project with Dr. Jonathan Lim (Institute of Neuropathology, UKD)

About the project: The major oncogenic driver in 25-30% of all human cancers arises from abnormal activation of RAS signaling pathways. Moreover, a number of mutant RAS-driven cancers such as pancreatic adenocarcinoma, and cancers with constitutive RAS signaling, such as glioblastoma, remain incurable. This drives the impetus for novel and more efficacious therapeutic strategies. The focus of the project is to gain a systems-level understanding of how oncogenic signaling from RAS activation leads to remodeling of the glycoproteome, an area that is poorly understood. We employ the use of engineered cell lines, bioorthogonal chemistry, and targeted mass spectrometry approaches to obtain a global view of glycan and proteome changes, as well as to specifically investigate how some of these changes directly contribute to tumorigenic phenotypes. These mechanisms will be recapitulated in clinically-relevant cancer models towards the development of novel therapeutic interventions for difficult-to-treat cancers.

 

Interne Vernetzungsförderung

Kategorie/n: MC Hartmann

Wir gratulieren Ulla Gerling-Driessen zur erfolgreich eingeworbenen Vernetzungsförderung

Zoom

 

This  is a collaborative project with Dr. Jonathan Lim (Institute of Neuropathology, UKD)

About the project: The major oncogenic driver in 25-30% of all human cancers arises from abnormal activation of RAS signaling pathways. Moreover, a number of mutant RAS-driven cancers such as pancreatic adenocarcinoma, and cancers with constitutive RAS signaling, such as glioblastoma, remain incurable. This drives the impetus for novel and more efficacious therapeutic strategies. The focus of the project is to gain a systems-level understanding of how oncogenic signaling from RAS activation leads to remodeling of the glycoproteome, an area that is poorly understood. We employ the use of engineered cell lines, bioorthogonal chemistry, and targeted mass spectrometry approaches to obtain a global view of glycan and proteome changes, as well as to specifically investigate how some of these changes directly contribute to tumorigenic phenotypes. These mechanisms will be recapitulated in clinically-relevant cancer models towards the development of novel therapeutic interventions for difficult-to-treat cancers.

 

Interne Vernetzungsförderung

Kategorie/n: MC Hartmann

Wir gratulieren Ulla Gerling-Driessen zur erfolgreich eingeworbenen Vernetzungsförderung

Zoom

 

This  is a collaborative project with Dr. Jonathan Lim (Institute of Neuropathology, UKD)

About the project: The major oncogenic driver in 25-30% of all human cancers arises from abnormal activation of RAS signaling pathways. Moreover, a number of mutant RAS-driven cancers such as pancreatic adenocarcinoma, and cancers with constitutive RAS signaling, such as glioblastoma, remain incurable. This drives the impetus for novel and more efficacious therapeutic strategies. The focus of the project is to gain a systems-level understanding of how oncogenic signaling from RAS activation leads to remodeling of the glycoproteome, an area that is poorly understood. We employ the use of engineered cell lines, bioorthogonal chemistry, and targeted mass spectrometry approaches to obtain a global view of glycan and proteome changes, as well as to specifically investigate how some of these changes directly contribute to tumorigenic phenotypes. These mechanisms will be recapitulated in clinically-relevant cancer models towards the development of novel therapeutic interventions for difficult-to-treat cancers.

 

Interne Vernetzungsförderung

Kategorie/n: MC Hartmann
Responsible for the content: